Medtide (HKSE:03880) Other Financing: HK$-41.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03880 Medtide Inc HKSE:03880
23 GF Score
Price HK$21.22
View Full Analysis

What is Medtide Other Financing?

Medtide HKSE:03880 +1.82% 23 Other Financing is HK$-41.0 Mil as of Dec. 2025. GuruFocus rates HKSE:03880 with a GF Score™ of 23/100.

Medtide's Other Financing for the six months ended in Dec. 2025 was HK$-40.5 Mil.

Medtide's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-41.0 Mil.

Medtide Other Financing Historical Data

* Premium members only.

The historical data trend for Medtide's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtide Other Financing Chart

Medtide Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
-31.61 -1.02 -22.97 -15.44 -41.03

Medtide Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only -7.63 -7.86 -0.53 -40.49 0.00
HKSE:03880
23GF Score
Medtide Inc HKSE:03880
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtide Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-41.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$-41.0 Mil mean?
Medtide (HKSE:03880) has a Other Financing of HK$-41.0 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Medtide and its competitors.
Is Medtide's Other Financing too high?
Medtide's current Other Financing is HK$-41.0 Mil. Overall, Medtide has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's Other Financing compare to VRTX and REGN?
Medtide's Other Financing of HK$-41.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Medtide and its competitors. Medtide's current Other Financing is HK$-41.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (HKSE:03880) has a current Other Financing of HK$-41.0 Mil. The current Other Financing is HK$-41.0 Mil. Medtide's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Medtide (HKSE:03880), the current Other Financing is HK$-41.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medtide Business Description

Other Exchanges FQ2:Germany
Address No. 69, 12 Street, Qiantang District, Zhejiang, Hangzhou, CHN
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
23GF Score

Get the complete analysis for HKSE:03880

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$21.22
Price